A trial to assess induction therapy with alemtuzumab versus basiliximab, followed by a three drug immunosuppression regimen, in patients undergoing a single, or double, lung transplant, or a combined heart-lung transplant.

Trial Profile

A trial to assess induction therapy with alemtuzumab versus basiliximab, followed by a three drug immunosuppression regimen, in patients undergoing a single, or double, lung transplant, or a combined heart-lung transplant.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Alemtuzumab (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate
  • Indications Heart-lung transplant rejection; Lung transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top